AstraZeneca (AZN.US) invests in Summit (SMMT.US), gaining positive outlooks from JPMorgan and Citi: Cancer drug strategy awaits validation

Zhitong Finance APP has learned that AstraZeneca (AZN.US) announced an investment in U.S. biotechnology company Summit Therapeutics (SMMT.US) and a collaboration on a new anti-cancer drug. Following the news, AstraZeneca rose about 2% in pre-market trading on Tuesday, while SMMT's gains expanded to around 23%. Analysts from JPMorgan and Citi welcomed the deal, saying it is consistent with AstraZeneca's cancer strategy.

According to reports, analysts led by Richard Vosser said in a report that JPMorgan (Overweight rating) believes this investment will enable AstraZeneca to test ivonescimab in its own pipeline, including in combination with its own Sone-V and a broader oncology portfolio, which includes antibody-drug conjugates (ADC). The bank stated that after the investment is completed, AstraZeneca will have rights equivalent to approximately a 12% stake in Summit.

Citi (Buy rating) stated: "This deal aligns with AstraZeneca's efforts—the company is working to make its expanding ADC portfolio a core pillar of its future oncology treatment solutions."

"We believe this deal is a strong external validation of ivonescimab and the PD-1/VEGF bispecific antibody asset class," analyst John Yung wrote in the report.